Genetic Testing in the Management of Adult CKD
Journal of the American Society of Nephrology · 2026-04 · 37 (4) · 777-789
DOI: 10.1681/asn.0000000913 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 29.10.2025. Verfasst von Fouad T Chebib und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida. Hauptthemen laut MEDLINE: Genetic Testing, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Natera.
Abstract (Originalsprache)
Key Points Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy.
Background
CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing.
Methods
The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point.
Results
In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding.
Conclusions
Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida.
- Department of Kidney Medicine, Center for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio.
- Nephrology Associates of Northern Illinois and Indiana, Chicago, Illinois.
- Natera, Inc., Austin, Texas.
- Division of Nephrology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
- South Texas Renal Care Group, San Antonio, Texas.
ORCID-Profile: Fouad T Chebib, Xiangling Wang, Suneel M Udani, Maggie Westemeyer, Michelle S Bloom, Hila Milo Rasouly, Mohammad R Mizani, Neville R Dossabhoy, Arman Faravardeh, Zachary P Demko, Sumit Punj, Steven L Chapman, Matthew Rabinowitz, Hossein Tabriziani, Sangeeta Bhorade, Neera K Dahl
Förderung
- NIDDK NIH HHS
- Natera
Zitieren
APA
Chebib, F. T., Wang, X., Udani, S. M., Westemeyer, M., Clark, D., Zhang, Z., Bloom, M. S., Milo Rasouly, H., Kolupaeva, V., Mizani, M. R., Dossabhoy, N. R., Faravardeh, A., Demko, Z. P., Kotte, S., Punj, S., Chapman, S. L., Rabinowitz, M., Schneider, R., Tabriziani, H., …, & Dahl, N. K. (2026). Genetic Testing in the Management of Adult CKD. Journal of the American Society of Nephrology, 37(4), 777-789. https://doi.org/10.1681/asn.0000000913
Vancouver
Chebib FT, Wang X, Udani SM, Westemeyer M, Clark D, Zhang Z, et al. Genetic Testing in the Management of Adult CKD. Journal of the American Society of Nephrology. 2026;37(4):777-789. doi:10.1681/asn.0000000913
BibTeX
@article{Chebib2026,
author = {Chebib, Fouad T and Wang, Xiangling and Udani, Suneel M and Westemeyer, Maggie and Clark, Dinah and Zhang, Zhiji and Bloom, Michelle S and Milo Rasouly, Hila and Kolupaeva, Victoria and Mizani, Mohammad R and Dossabhoy, Neville R and Faravardeh, Arman and Demko, Zachary P and Kotte, Sri and Punj, Sumit and Chapman, Steven L and Rabinowitz, Matthew and Schneider, Ronen and Tabriziani, Hossein and Bhorade, Sangeeta and Gharavi, Ali G and Dahl, Neera K},
title = {Genetic Testing in the Management of Adult CKD},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {4},
pages = {777--789},
doi = {10.1681/asn.0000000913}
}
EUVIMED